The JOM11 Framework: Concierge Psychedelic Therapy for Executives

Why Senior Leaders Are Looking at Psychedelic Therapy Differently Now

The conversation has changed. Psychedelic-assisted therapy is no longer on the fringes of mental health research. It is being studied at Johns Hopkins, NYU, and Imperial College London. The FDA granted psilocybin “breakthrough therapy” designation for treatment-resistant depression in 2018 and for major depressive disorder in 2019. Peer-reviewed trials are now examining its effects specifically in high-functioning, high-pressure populations.

For executives and senior leaders, the relevant question is not whether psychedelic therapy is legitimate. It is whether there is a program rigorous enough, private enough, and structured enough to be worth their time and trust. That is the question JOM11 was built to answer.

What JOM11 Is, and What It Is Not

JOM11 is JourneyOM’s concierge psychedelic therapy pathway for executives, CEOs, and senior professionals. It is not a retreat. It is not a loosely coordinated “journey” with a guide you met once. It is a structured eleven-touchpoint program that moves a client through a deliberate sequence: clinical assessment, guide matching, preparation sessions, the supported experience itself, and a defined integration arc.

The eleven touchpoints are not arbitrary. They reflect what the clinical literature consistently identifies as the variables that determine outcomes: depth of preparation, quality of the therapeutic relationship, and the structured processing of insights afterward. Skip or compress any of these, and the evidence suggests you are leaving most of the value on the table.

The target outcomes for this program are psychological in nature, not mystical. We are talking about reduced cognitive rigidity, improved emotional regulation, measurable reductions in burnout symptoms, and a clearer relationship with chronic stress patterns that are, at this point, often invisible to the executive carrying them.

The Neuroscience Behind the Outcomes Executives Are Seeking

Senior leaders tend to be analytical. So it is worth being direct about what the neuroscience actually shows, and where the evidence is still developing.

Psilocybin acts primarily as a serotonin 5-HT2A receptor agonist. In neuroimaging studies, it consistently disrupts resting-state connectivity within the default mode network (DMN), the brain network most associated with self-referential thinking, habitual mental patterns, and rumination. Simultaneously, it increases functional connectivity between networks that do not normally communicate as freely. A 2023 systematic review in the International Journal of Neuropsychopharmacology found this pattern of DMN disruption and increased inter-network connectivity across multiple psychedelic agents, and noted that a more flexible brain state was observed to persist in patients with major depressive disorder following psilocybin treatment.

A 2021 open-label study (PMC8575795) found that psilocybin therapy increased cognitive flexibility for at least four weeks post-treatment in patients with major depressive disorder, measured via perseverative errors on a set-shifting task. This is the kind of metric that has direct relevance for executive performance: the ability to shift perspective, update mental models under pressure, and avoid the kind of calcified thinking that tends to accumulate over decades in high-stakes roles.

On burnout specifically, a 2025 randomized controlled trial published in PLOS Medicine examined psilocybin-assisted psychotherapy combined with mindfulness-based stress reduction in frontline healthcare providers with symptoms of depression and burnout. Participants showed statistically significant decreases in depressive symptoms at both the two-week and six-month post-intervention marks. The burnout measures trended in the same direction, though the researchers noted that sample size limited statistical significance on that endpoint. This is where the evidence is headed, not where it has fully arrived. Anyone presenting this as a proven treatment for burnout is overstating it. Anyone dismissing it as unproven is not reading the literature.

The JOM11 Sequence: What Each Phase Is Actually Doing

Phase 1: Assessment

The program begins with a structured clinical and psychological assessment. This is not a sales call. It is a rigorous evaluation of whether the client is an appropriate candidate, what their specific goals are, and what contraindications, if any, need to be addressed before proceeding. Executives often arrive at this step with a clear hypothesis about what they want to resolve. The assessment either validates that hypothesis or reframes it. Both outcomes are useful.

Everything disclosed in the assessment is protected. No information from the JOM11 intake process is shared with employers, boards, or third parties. This point matters: many senior leaders have spent careers in environments where disclosing vulnerability carries professional risk. JOM11 operates entirely outside that structure.

Phase 2: Guide Matching

JourneyOM’s model is a concierge psychedelic therapy platform. That means we do not assign guides; we match them. The matching process accounts for the client’s professional background, psychological profile, stated goals, and communication style. For executives specifically, this often means working with guides who have experience in high-performance contexts and can engage at the level of nuance and complexity that comes with the territory.

The guide relationship is not incidental. It is a primary variable in outcomes. Research on psychedelic-assisted therapy consistently identifies the therapeutic relationship and the quality of preparation as central to what a session produces. A poorly matched guide wastes the experience.

Phase 3: Preparation

Preparation in the JOM11 program involves multiple structured sessions with the assigned guide before any experience takes place. The work here is practical. It includes establishing goals, identifying the psychological patterns most relevant to those goals, setting the parameters of the experience itself, and developing the client’s capacity to work with difficult material if it arises.

For executives, preparation often surfaces things that have not had much airtime: chronic stress responses that have become normalized, relational patterns that affect team dynamics, the cognitive habits that come with operating at a high level for a long time. The experience works with whatever material is present. The preparation shapes what that material is and how the client is positioned to engage with it.

Phase 4: The Supported Experience

The experience itself takes place in a controlled setting with professional guide support throughout. Logistics, location, and specific protocols are arranged as part of the concierge layer of the program and are tailored to the client’s context and jurisdiction.

The acute phase, which typically runs between four and six hours, is not the primary site of value on its own. Neuroimaging research consistently shows that the acute effects of psilocybin involve temporary disruption of normal brain network organization, which is precisely what allows fixed patterns to become accessible. The lasting value comes from what happens in integration, not from the experience in isolation.

Phase 5: Integration

Integration is where most programs fail executives, and where JOM11 invests the most structure. The integration phase of the program includes multiple follow-up sessions with the guide, structured reflection frameworks, and ongoing support through JourneyOM’s continuity-of-care system.

For a senior leader, integration is not journaling. It is the deliberate process of translating insight into behavior: identifying which of the patterns that surfaced in the experience are relevant to current professional or personal challenges, what specifically needs to change, and how to build accountability around those changes. This is cognitive-behavioral work, not processing for its own sake.

Who This Program Is For

The JOM11 psychedelic executive program is designed for individuals who are functioning at a high level by most external metrics but have arrived at a point where conventional approaches have stopped producing the gains they are looking for. That profile is common among executives in their 40s and 50s. The performance infrastructure is intact. The drive is intact. But something in the signal-to-noise ratio has shifted. Decision fatigue is higher. Emotional regulation under pressure is less consistent. The quality of thinking in certain domains has become less flexible.

It is also designed for leaders who are managing significant chronic stress loads or early-stage burnout, and who want to address that at the root rather than through temporary compensatory strategies.

It is not appropriate for everyone, and the assessment phase exists to make that determination honestly. Contraindications are real, and JourneyOM does not enroll clients for whom the program is not a suitable fit.

What “Concierge” Actually Means in This Context

Concierge psychedelic therapy for CEOs and senior leaders is not a premium label applied to a standard product. In the JOM11 context, it means the following: a single point of contact through JourneyOM throughout the entire program, no administrative burden on the client, logistics handled discreetly and completely, guide selection based on fit rather than availability, and a level of follow-through after the experience that most programs do not provide.

Executives operate in environments where their time is the limiting factor and their privacy is a genuine operational concern. The concierge model exists to remove every structural obstacle between the client and the work.

A Note on Legal Context

The legal landscape for psychedelic-assisted therapy varies significantly by jurisdiction and is evolving. JourneyOM operates within legal frameworks and does not facilitate experiences outside of them. Part of the intake process includes a clear, jurisdiction-specific conversation about what options are available and what the regulatory environment currently permits. This is not a program that asks clients to assume legal risk.